Open Orphan PLC Rule 2.9 Announcement (2648W)

TIDMORPH

RNS Number : 2648W

Open Orphan PLC

10 December 2019

Open Orphan plc

("Open Orphan or the "Company")

Rule 2.9 Announcement

In accordance with Rule 2.9 of the City Code on takeovers and Mergers, the Company confirms that, as at the close of business on 9 December 2019, being the last business day prior to the date of this announcement, it had 254,572,567 ordinary shares of 0.1 pence each in issue. The Company holds no ordinary shares in treasury. Accordingly, the total number of voting rights in Open Orphan is 254,572,567. The International Securities Identification Number ("ISIN") for Open Orphan's ordinary shares is GB00B9275X97.

For further information please contact:

Open Orphan plc +353 (0)1 644 0007

Cathal Friel, Chief Executive Officer

   Arden Partners plc (Nominated Adviser and Joint Broker)                    +44 (0)20 7614 5900

John Llewellyn-Lloyd / Benjamin Cryer

   Davy (Euronext Growth Adviser and Joint Broker)                                +353 (0)1 679 6363

Anthony Farrell

Camarco (Financial PR) +44 (0)20 3757 4980

Tom Huddart / Billy Clegg / Daniel Sherwen

Notes to Editors:

Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RTTBLBDDGUGBGCC

(END) Dow Jones Newswires

December 10, 2019 02:01 ET (07:01 GMT)

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024